Cargando…
Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine
Lyme disease is the most common vector-borne disease in North America. The etiological agent is the spirochete Borreliella burgdorferi, transmitted to mammalian hosts by the Ixodes tick. In recent years there has been an increase in the number of cases of Lyme disease. Currently, there is no vaccine...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553707/ https://www.ncbi.nlm.nih.gov/pubmed/32783701 http://dx.doi.org/10.1080/21645515.2020.1789408 |
_version_ | 1783593658567622656 |
---|---|
author | Guibinga, Ghiabe H. Sahay, Bikash Brown, Heather Cooch, Neil Chen, Jing Yan, Jian Reed, Charles Mishra, Meerambika Yung, Bryan Pugh, Holly Schultheis, Katherine Esquivel, Rianne N. Weiner, David B. Humeau, Laurent H. Broderick, Kate E. Smith, Trevor R.F. |
author_facet | Guibinga, Ghiabe H. Sahay, Bikash Brown, Heather Cooch, Neil Chen, Jing Yan, Jian Reed, Charles Mishra, Meerambika Yung, Bryan Pugh, Holly Schultheis, Katherine Esquivel, Rianne N. Weiner, David B. Humeau, Laurent H. Broderick, Kate E. Smith, Trevor R.F. |
author_sort | Guibinga, Ghiabe H. |
collection | PubMed |
description | Lyme disease is the most common vector-borne disease in North America. The etiological agent is the spirochete Borreliella burgdorferi, transmitted to mammalian hosts by the Ixodes tick. In recent years there has been an increase in the number of cases of Lyme disease. Currently, there is no vaccine on the market for human use. We describe the development of a novel synthetically engineered DNA vaccine, pLD1 targeting the outer-surface protein A (OspA) of Borreliella burgdorferi. Immunization of C3 H/HeN mice with pLD1 elicits robust humoral and cellular immune responses that confer complete protection against a live Borreliella burgdorferi bacterial challenge. We also assessed intradermal (ID) delivery of pLD1 in Hartley guinea pigs, demonstrating the induction of robust and durable humoral immunity that lasts at least 1 year. We provide evidence of the potency of pLD1 by showing that antibodies targeting the OspA epitopes which have been associated with protection are prominently raised in the immunized guinea pigs. The described study provides the basis for the advancement of pDL1 as a potential vaccine for Lyme disease control. |
format | Online Article Text |
id | pubmed-7553707 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-75537072020-10-23 Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine Guibinga, Ghiabe H. Sahay, Bikash Brown, Heather Cooch, Neil Chen, Jing Yan, Jian Reed, Charles Mishra, Meerambika Yung, Bryan Pugh, Holly Schultheis, Katherine Esquivel, Rianne N. Weiner, David B. Humeau, Laurent H. Broderick, Kate E. Smith, Trevor R.F. Hum Vaccin Immunother Research Paper Lyme disease is the most common vector-borne disease in North America. The etiological agent is the spirochete Borreliella burgdorferi, transmitted to mammalian hosts by the Ixodes tick. In recent years there has been an increase in the number of cases of Lyme disease. Currently, there is no vaccine on the market for human use. We describe the development of a novel synthetically engineered DNA vaccine, pLD1 targeting the outer-surface protein A (OspA) of Borreliella burgdorferi. Immunization of C3 H/HeN mice with pLD1 elicits robust humoral and cellular immune responses that confer complete protection against a live Borreliella burgdorferi bacterial challenge. We also assessed intradermal (ID) delivery of pLD1 in Hartley guinea pigs, demonstrating the induction of robust and durable humoral immunity that lasts at least 1 year. We provide evidence of the potency of pLD1 by showing that antibodies targeting the OspA epitopes which have been associated with protection are prominently raised in the immunized guinea pigs. The described study provides the basis for the advancement of pDL1 as a potential vaccine for Lyme disease control. Taylor & Francis 2020-08-12 /pmc/articles/PMC7553707/ /pubmed/32783701 http://dx.doi.org/10.1080/21645515.2020.1789408 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Research Paper Guibinga, Ghiabe H. Sahay, Bikash Brown, Heather Cooch, Neil Chen, Jing Yan, Jian Reed, Charles Mishra, Meerambika Yung, Bryan Pugh, Holly Schultheis, Katherine Esquivel, Rianne N. Weiner, David B. Humeau, Laurent H. Broderick, Kate E. Smith, Trevor R.F. Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine |
title | Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine |
title_full | Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine |
title_fullStr | Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine |
title_full_unstemmed | Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine |
title_short | Protection against Borreliella burgdorferi infection mediated by a synthetically engineered DNA vaccine |
title_sort | protection against borreliella burgdorferi infection mediated by a synthetically engineered dna vaccine |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553707/ https://www.ncbi.nlm.nih.gov/pubmed/32783701 http://dx.doi.org/10.1080/21645515.2020.1789408 |
work_keys_str_mv | AT guibingaghiabeh protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT sahaybikash protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT brownheather protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT coochneil protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT chenjing protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT yanjian protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT reedcharles protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT mishrameerambika protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT yungbryan protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT pughholly protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT schultheiskatherine protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT esquivelriannen protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT weinerdavidb protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT humeaulaurenth protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT broderickkatee protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine AT smithtrevorrf protectionagainstborreliellaburgdorferiinfectionmediatedbyasyntheticallyengineereddnavaccine |